OSL (ASX) OncoSil Insurance Adoption

Originally posted by tinyteddy: ↑

Both.

I think if the next 10-20 percutaneous implants of Oncosil are shown to be safe it will turn the company into a really exciting prospect. Interventional radiology opens many doors for the product. It also probably means that the pivotal trials in the US will be done with percutaneous implantation and not endoscopic, which means the label will be a good one and the reimbursement will be based on that method.

And if the recently started TRIPP study confirms the findings of the previous studies and the Osprey register but in an RCT format then once again it will be fantastic and uptake will be significant. I won;t say anything about FDA because that seems stuck for now, but it's still there.

It's just about the cashflow. Once the German trial is approved it will be cashflow positive, but its hard to know how much and how quickly it will contribute to the bottom line. Also it will still take time to confirm reimbursement after the trials are finished. I know that these studies will also lead to more private sales as they progress, but government reimbursement is the key. And with government reimbursement, although each country is separate, there's definitely a domino effect where citizens will say what about us.

I think we are 1-2 years from self sustaining cashflow after which it will take off. So either the company raises from shareholders again or does a deal. If a full takeover offer came for the company now it would be giving away a lot of potential for not much given the shareprice is so bad.

In some ways that's the core problem. All the progress made in the last 2 years isn't reflected in the shareprice at all. The successful first percutaneous implant should have doubled the shareprice last week, but it made no impact at all. I know posters here will say show me the cash. But as I've said, there are medtech and biotechs with no approved products buring lots of cash with MC far above ours for reasons I don;t understand...except perhaps that the history of the company prior to the last few years has been not great. Some analyst coverage is really needed to get the message out there. Some institutions/funds need to look at this story and be convinced as I am that the potential is closer than ever..

Take a look at senior management and Board now. Look at the percutaneous implants. Look at the TRIPP RCT and the coming German trial. Look at the new manufacturing site in Sydney. I mean it's a proper medtech with a huge unmet market need. It's doing things properly now. If it were to be sold for peanuts because it can;t find the next 15 million it would be a sad outcome for shareholders who have paid to get it here.

Expand

Have to agree with you on this one TT beginning the percutaneous trial is a major step forward that we have all been waiting for. Do you think that the Germans will wait to see how the Dutch trial goes and pivot the GBA trial to percutaneous as that would much more cost effective in terms of implanting the device.
If I was the one who was signing off on the GBA trial it would be on my mind to watch and see how successful the Amsterdam trial is.

No.	Vol.	Price($)
29	23118264	0.4¢

No.

Vol.

Price($)

23118264

0.4¢

Price($)	Vol.	No.
0.5¢	5200224	7

Price($)

Vol.

No.

0.5¢

5200224

No.	Vol.	Price($)
27	20618264	0.004
8	4673547	0.003
6	5457516	0.002
4	7800000	0.001
0	0	0.000

No.

Vol.

Price($)

20618264

0.004

4673547

0.003

5457516

0.002

7800000

0.001

0.000

Price($)	Vol.	No.
0.005	5200224	7
0.006	20507648	25
0.007	24737500	19
0.008	9543848	10
0.009	12462253	5

Price($)

Vol.

No.

0.005

5200224

0.006

20507648

0.007

24737500

0.008

9543848

0.009

12462253

(20min delay)
Last 0.4¢		Change -0.001(11.1%)		Mkt cap ! $13.32M

Open	High	Low	Value	Volume
0.5¢	0.5¢	0.4¢	$23.68K	4.971M

OncoSil Insurance Adoption, page-11

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Recce's R327 found effective against E.coli during clinical trial

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Ava Risk Group expands US presence with A$0.7M Substation Deal

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

OncoSil Insurance Adoption, page-11

Top Stories

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Recce's R327 found effective against E.coli during clinical trial

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Microcap Wrap: 5 explorers with news out today

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Ava Risk Group expands US presence with A$0.7M Substation Deal

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News